In this era of escalating trade tensions and geopolitical uncertainty, the U.S. cannot afford to cede another critical ...

70. If the last few months are any guide, there will be no shortage of surprises and challenges for the biotech industry in the new year. Donald Trump will begin his second term, possibly bringing ...

Western drugmakers, investors increasingly aim to acquire Chinese compounds.

The biotech industry’s DeepSeek moment came last fall. That is when Summit Therapeutics, backed by billionaire Bob Duggan, ...

The Biotech industry has underperformed due to the Trump administration, RFK Jr.'s skepticism, and funding uncertainty, with major ETFs down 19-25% over six months. Some biotech companies with ...